Prostatype Genomics AB (ST:PROGEN) — Market Cap & Net Worth
Market Cap & Net Worth: Prostatype Genomics AB (PROGEN)
Prostatype Genomics AB (ST:PROGEN) has a market capitalization of $3.39 Million (Skr31.49 Million) as of June 17, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #29271 globally and #670 in its home market, demonstrating a 6.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Prostatype Genomics AB's stock price Skr0.53 by its total outstanding shares 59189321 (59.19 Million). Review PROGEN total liabilities to assess the company's total debt and financial obligations.
Prostatype Genomics AB Market Cap History: 2020 to 2026
Prostatype Genomics AB's market capitalization history from 2020 to 2026. Data shows change from $9.18 Billion to $3.39 Million (-72.18% CAGR).
Index Memberships
Prostatype Genomics AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$16.06 Billion | 0.02% | #213 of 281 |
Weight: Prostatype Genomics AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Prostatype Genomics AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Prostatype Genomics AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
355.30x
Prostatype Genomics AB's market cap is 355.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $9.18 Billion | $683.88K | -$17.41 Million | 13421.19x | N/A |
| 2021 | $5.74 Billion | $10.00K | -$15.63 Million | 573813.92x | N/A |
| 2022 | $1.36 Billion | $683.00K | -$29.09 Million | 1992.27x | N/A |
| 2023 | $284.22 Million | $1.36 Million | -$41.44 Million | 209.61x | N/A |
| 2024 | $70.70 Million | $199.00K | -$41.05 Million | 355.30x | N/A |
Competitor Companies of PROGEN by Market Capitalization
Companies near Prostatype Genomics AB in the global market cap rankings as of June 17, 2026.
Key companies related to Prostatype Genomics AB by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Prostatype Genomics AB Historical Marketcap From 2020 to 2026
Between 2020 and today, Prostatype Genomics AB's market cap moved from $9.18 Billion to $ 3.39 Million, with a yearly change of -72.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr3.39 Million | +77.33% |
| 2025 | Skr1.91 Million | -97.30% |
| 2024 | Skr70.70 Million | -75.12% |
| 2023 | Skr284.22 Million | -79.11% |
| 2022 | Skr1.36 Billion | -76.29% |
| 2021 | Skr5.74 Billion | -37.48% |
| 2020 | Skr9.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Prostatype Genomics AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.39 Million USD |
| MoneyControl | $3.39 Million USD |
| MarketWatch | $3.39 Million USD |
| marketcap.company | $3.39 Million USD |
| Reuters | $3.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Prostatype Genomics AB
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doct… Read more